The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Italy could have AstraZeneca COVID-19 shots by end November, IRBM biotech says

Wed, 16th Sep 2020 19:13

ROME, Sept 16 (Reuters) - Italy could have its first shots
of British drugmaker AstraZeneca's potential COVID-19
vaccine by the end of November, the managing director of IRBM
told Reuters.

Biotech firm IRBM, whose lab is based south of Rome, is
cooperating with AstraZeneca in developing a vaccine for the
disease which has caused more than 35,600 deaths in Italy.

"It is possible to have the first shots in Italy by the end
of November, provided the trial continues as planned and the
vaccine is validated," Matteo Liguori said on Wednesday.

Italy's Health Minister had already said the vaccine could
be available by the end of 2020.
(Reporting by Emilio Parodi; Writing by Angelo Amante; Editing
by Alexander Smith)

Related Shares

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.